238 related articles for article (PubMed ID: 35483554)
21. Fluorescence-Quenching Lateral Flow Immunoassay for "Turn-On" and Sensitive Detection of Anti-SARS-Cov-2 Neutralizing Antibodies in Human Serum.
Bian L; Fu Q; Gan Z; Wu Z; Song Y; Xiong Y; Hu F; Zheng L
Adv Sci (Weinh); 2024 Jan; 11(4):e2305774. PubMed ID: 38032112
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
23. Overlaid Lateral Flow Immunoassay for the Simultaneous Detection of Two Variant-Specific SARS-CoV-2 Neutralizing Antibodies.
Deenin W; Khongchareonporn N; Ruxrungtham K; Ketloy C; Hirankarn N; Wangkanont K; Rengpipat S; Yakoh A; Chaiyo S
Anal Chem; 2024 Apr; 96(14):5407-5415. PubMed ID: 38478766
[TBL] [Abstract][Full Text] [Related]
24. Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.
Shurrab FM; Younes N; Al-Sadeq DW; Liu N; Qotba H; Abu-Raddad LJ; Nasrallah GK
Int J Infect Dis; 2022 May; 118():132-137. PubMed ID: 35231609
[TBL] [Abstract][Full Text] [Related]
25. Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum.
Bian L; Li Z; He A; Wu B; Yang H; Wu Y; Hu F; Lin G; Zhang D
Biomaterials; 2022 Sep; 288():121694. PubMed ID: 35977850
[TBL] [Abstract][Full Text] [Related]
26. Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS-CoV-2 in clinical samples using a smartphone-based application.
Prakashan D; Shrikrishna NS; Byakodi M; Nagamani K; Gandhi S
J Med Virol; 2023 Jan; 95(1):e28416. PubMed ID: 36541714
[TBL] [Abstract][Full Text] [Related]
27. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
Yun S; Ryu JH; Jang JH; Bae H; Yoo SH; Choi AR; Jo SJ; Lim J; Lee J; Ryu H; Cho SY; Lee DG; Lee J; Kim SC; Park YJ; Lee H; Oh EJ
Ann Lab Med; 2021 Nov; 41(6):577-587. PubMed ID: 34108285
[TBL] [Abstract][Full Text] [Related]
28. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
[TBL] [Abstract][Full Text] [Related]
30. Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants.
Lunderberg JM; Dutta S; Collier AY; Lee JS; Hsu YM; Wang Q; Zheng W; Hao S; Zhang H; Feng L; Robson SC; Gao W; Riedel S
Front Immunol; 2022; 13():1032574. PubMed ID: 36389829
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
32. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
33. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
34. Development of spike protein-based fluorescence lateral flow assay for the simultaneous detection of SARS-CoV-2 specific IgM and IgG.
Wang C; Shi D; Wan N; Yang X; Liu H; Gao H; Zhang M; Bai Z; Li D; Dai E; Rong Z; Wang S
Analyst; 2021 Jun; 146(12):3908-3917. PubMed ID: 33970172
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a rapid and easy-to-perform point-of-care lateral flow immunoassay (LFIA) for the detection of SARS-CoV-2 spike protein.
Mohammad S; Wang Y; Cordero J; Watson C; Molestina R; Rashid S; Bradford R
Front Immunol; 2023; 14():1111644. PubMed ID: 36911726
[TBL] [Abstract][Full Text] [Related]
36. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer.
Connelly GG; Kirkland OO; Bohannon S; Lim DC; Wilson RM; Richards EJ; Tay DM; Jee H; Hellinger RD; Hoang NK; Hao L; Chhabra A; Martin-Alonso C; Tan EKW; Koehler AN; Yaffe MB; London WB; Lee PY; Krammer F; Bohannon RC; Bhatia SN; Sikes HD; Li H
Cell Rep Methods; 2022 Aug; 2(8):100273. PubMed ID: 35942328
[TBL] [Abstract][Full Text] [Related]
37. Sensitive SARS-CoV-2 salivary antibody assays for clinical saline gargle samples using smartphone-based competitive particle immunoassay platforms.
Liang Y; Buchanan BC; Khanthaphixay B; Zhou A; Quirk G; Worobey M; Yoon JY
Biosens Bioelectron; 2023 Jun; 229():115221. PubMed ID: 36958205
[TBL] [Abstract][Full Text] [Related]
38. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.
Kang K; Huang L; Ouyang C; Du J; Yang B; Chi Y; He S; Ying L; Chen G; Wang J
J Med Virol; 2021 May; 93(5):2838-2847. PubMed ID: 33231312
[TBL] [Abstract][Full Text] [Related]
39. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
40. The utility of smartphone-based quantitative analysis of SARS-CoV-2-specific antibody lateral flow assays.
Uwamino Y; Tanaka S; Shibata A; Kurafuji T; Ishihara H; Sato Y; Matsushita H
Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116166. PubMed ID: 38157638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
